VetDC, Inc., a veterinary cancer therapeutics company, announced yesterday that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has granted a conditional approval of Tanovea-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs. Tanovea-CA1 is anticipated to be available to veterinarians in the spring of 2017.
“This is a significant milestone for VetDC, and we are excited to announce the first ever FDA-approved drug for canine lymphoma,” said Steven Roy, VetDC’s president and CEO. “We look forward to introducing Tanovea-CA1 to the veterinary cancer community in the months to come.”
“The conditional approval of Tanovea-CA1 represents a first on multiple levels for veterinary oncology, and we eagerly anticipate adding this very active and promising new drug to our lymphoma fighting arsenal,” noted Dr. Philip J. Bergman, a board-certified veterinary oncologist at VCA-Katonah Bedford Veterinary Center in Bedford Hills, New York.